Poster: CLL-039: Pirtobrutinib (LOXO-305), a Next-Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Results from the Phase 1/2 BRUIN Study

Authors :: Catherine C. Coombs
John M. Pagel
Nirav N. Shah
Nicole Lamanna
Ewa Lech-Maranda
Toby A. Eyre
Jennifer A. Woyach
William G Wierda
Chan Y. Cheah
Lindsey Roeker
Manish R. Patel
Bita Fakhri
Minal A. Barve
Constantine S. Tam
David J. Lewis
James N. Gerson
Alvaro Alencar
Justin Taylor
Omar Abdel-Wahab
Paolo Ghia
Stephen J. Schuster
Jessica Chen
Binoj Nair
Donald E. Tsai
Nora C. Ku
Matthew S. Davids
Jennifer R. Brown
Wojciech Jurczak
Anthony R. Mato
Source :: Clinical Lymphoma Myeloma and Leukemia. 21:S221
Publication Year :: 2021
Publisher :: Elsevier BV, 2021.

Full Text Access

Tools